EG626215 Activators
Ccdc196, a coiled-coil domain-containing protein, plays a crucial role in cellular processes yet to be fully elucidated. Activation of Ccdc196 is intricately regulated by various chemicals that directly or indirectly modulate its expression and functional role. The function of Ccdc196 appears to involve coiled-coil domain interactions, possibly participating in cellular structural dynamics or signaling pathways.
Ccdc196 activation mechanisms involve epigenetic modulators like Trichostatin A, Sodium Butyrate, and 5-Aza-2'-deoxycytidine, which influence histone acetylation and DNA demethylation at the Ccdc196 promoter, respectively. Additionally, inhibitors of TGF-β/Smad signaling (SB431542), GSK-3 (GSK-3 Inhibitor IX and CHIR99021), JNK (JNK Inhibitor II and SP600125), PI3K/Akt (LY294002), and MEK/ERK (MEK Inhibitor and Trametinib) pathways directly activate Ccdc196. Each of these chemicals establishes a unique mechanism by either directly interacting with Ccdc196 or modulating specific signaling pathways connected to its activation. Despite the detailed understanding of these activation mechanisms, the precise cellular processes and pathways influenced by Ccdc196 remain elusive. Further research is warranted to uncover the specific functions and downstream effects of Ccdc196 activation, shedding light on its role in cellular physiology and potential implications in various biological contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A activates Ccdc196 by inhibiting histone deacetylases, leading to increased histone acetylation at the Ccdc196 promoter. This epigenetic modification creates a permissive chromatin state, facilitating enhanced Ccdc196 expression and promoting cellular responses associated with its function. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium Butyrate activates Ccdc196 by inhibiting histone deacetylases, promoting histone acetylation at the Ccdc196 promoter. This epigenetic modulation establishes a permissive chromatin environment, facilitating increased Ccdc196 expression and contributing to cellular responses associated with its functional role. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2'-deoxycytidine activates Ccdc196 by inhibiting DNA methyltransferases, leading to DNA demethylation at the Ccdc196 promoter. This epigenetic alteration enhances Ccdc196 expression, creating an environment conducive to its functional role and promoting cellular responses associated with Ccdc196 activation. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic Acid activates Ccdc196 through HDAC inhibition, leading to increased histone acetylation at the Ccdc196 promoter. This epigenetic modulation establishes a chromatin state favorable for enhanced Ccdc196 expression, contributing to cellular responses associated with its functional role. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 activates Ccdc196 by inhibiting the TGF-β/Smad signaling pathway. This inhibition leads to increased Ccdc196 expression and promotes cellular responses associated with its function. SB431542's role in modulating TGF-β/Smad signaling establishes a direct mechanism for the activation of Ccdc196. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
GSK-3 Inhibitor IX activates Ccdc196 by inhibiting GSK-3, leading to increased β-catenin stabilization. This activation enhances Ccdc196 expression and promotes cellular responses associated with its functional role. The modulation of the Wnt/β-catenin pathway establishes a direct mechanism for Ccdc196 activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK Inhibitor II activates Ccdc196 by inhibiting c-Jun N-terminal kinase (JNK), leading to decreased phosphorylation of c-Jun. This modulation enhances Ccdc196 expression and promotes cellular responses associated with its functional role. JNK Inhibitor II's role in JNK pathway inhibition establishes a direct mechanism for Ccdc196 activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 activates Ccdc196 by inhibiting PI3K/Akt signaling. This inhibition leads to increased Ccdc196 expression and promotes cellular responses associated with its functional role. LY294002's role in modulating PI3K/Akt signaling establishes a direct mechanism for the activation of Ccdc196. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib activates Ccdc196 by inhibiting MEK in the MAPK/ERK pathway. This inhibition leads to increased Ccdc196 expression and promotes cellular responses associated with its functional role. Trametinib's role in modulating the MAPK/ERK pathway establishes a direct mechanism for the activation of Ccdc196. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
GSK-3 Inhibitor XVI activates Ccdc196 by inhibiting GSK-3, leading to increased β-catenin stabilization. This activation enhances Ccdc196 expression and promotes cellular responses associated with its functional role. CHIR99021's role in modulating the Wnt/β-catenin pathway establishes a direct mechanism for Ccdc196 activation. | ||||||